Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M0WM
|
|||
| Former ID |
DIB014477
|
|||
| Drug Name |
ATI-355
|
|||
| Synonyms |
Atinumab; Anti-Nogo-A mAbs, Novartis; Anti-Nogo-A monoclonal antibodies, Novartis; 11C7; 7B12
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Nerve injury [ICD-11: ND56.4; ICD-10: T14.4] | Phase 1 | [1] | |
| Company |
Novartis AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Reticulon-4 (RTN4) | Target Info | . | [2] |
| Pathway Interaction Database | p75(NTR)-mediated signaling | |||
| Reactome | Axonal growth inhibition (RHOA activation) | |||
| WikiPathways | Spinal Cord Injury | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00406016) Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI. U.S. National Institutes of Health. | |||
| REF 2 | Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 June; 135(6): 1794-1818. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.